Reselute

Reselute

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://reselutemedical.com/

Last Round

Seed Round

Apr 27, 2026

Total Funding Raised

$1.33M

Momentum Score

25 /100

Company Overview

Reselute is a therapeutic devices company that develops solutions for the treatment of orthopedic-related infections.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Advanced Materials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

drug-eluting implantslocalized antibiotic deliveryresorbable orthopedic implantsbioabsorbable implantsorthopedic implant infectionload-bearing implantsintramedullary nailbone infection treatmentIM nailtibial nailperiprosthetic joint infectionPJIfracture-related infectionsurgical site infectionSSIorthopedic spacersmedtechFDA Breakthrough Device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Reselute Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Reselute Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Seed RoundApr 27, 2026
GrantJul 15, 2024
SeedMay 18, 2023
GrantSep 1, 2022
GrantMay 5, 2022

Key People

Founding team and executive leadership

Cambre Kelly

Chief Executive Officer

Executive Team

Fioleda Prifti Kesseli

Chief Technology Officer

Executive Team

Omar Alaa Eldeen

Chief Technology Officer

Executive Team

Reselute Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Raised $2.39M in Seed funding.

  • Jul 15, 2024

    $999K grant awarded by the National Science Foundation.

Reselute Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Reselute Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Reselute's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range8
Year Founded2021
Last FundingApr 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.